Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
奈拉替尼联合达沙替尼在体外和体内对HER2阳性乳腺癌具有高度协同作用。
期刊:Translational Oncology
影响因子:4.1
doi:10.1016/j.tranon.2024.102073
Conlon, Neil T; Roche, Sandra; Mahdi, Amira F; Browne, Alacoque; Breen, Laura; Gaubatz, Johanna; Meiller, Justine; O'Neill, Fiona; O'Driscoll, Lorraine; Cremona, Mattia; Hennessy, Bryan T; Eli, Lisa D; Crown, John; Collins, Denis M
